RaySearch Laboratories AB (publ)
RSLBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,192 | $1,022 | $844 | $642 |
| % Growth | 16.6% | 21.2% | 31.5% | – |
| Cost of Goods Sold | $99 | $107 | $95 | $50 |
| Gross Profit | $1,093 | $916 | $749 | $591 |
| % Margin | 91.7% | 89.6% | 88.7% | 92.1% |
| R&D Expenses | $269 | $238 | $239 | $233 |
| G&A Expenses | $250 | $195 | $172 | $122 |
| SG&A Expenses | $576 | $558 | $481 | $422 |
| Sales & Mktg Exp. | $327 | $363 | $309 | $300 |
| Other Operating Expenses | -$14 | $5 | -$2 | -$0 |
| Operating Expenses | $832 | $801 | $718 | $655 |
| Operating Income | $260 | $115 | $43 | -$53 |
| % Margin | 21.9% | 11.2% | 5.1% | -8.2% |
| Other Income/Exp. Net | $2 | -$5 | -$10 | -$5 |
| Pre-Tax Income | $263 | $110 | $32 | -$59 |
| Tax Expense | $59 | $29 | $9 | -$11 |
| Net Income | $204 | $82 | $24 | -$47 |
| % Margin | 17.1% | 8% | 2.8% | -7.4% |
| EPS | 5.94 | 2.38 | 0.69 | -1.38 |
| % Growth | 149.6% | 244.9% | 150% | – |
| EPS Diluted | 5.94 | 2.38 | 0.69 | -1.38 |
| Weighted Avg Shares Out | 34 | 34 | 34 | 34 |
| Weighted Avg Shares Out Dil | 34 | 34 | 34 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $5 | $1 | $1 |
| Interest Expense | $9 | $10 | $11 | $6 |
| Depreciation & Amortization | $299 | $286 | $297 | $250 |
| EBITDA | $571 | $406 | $341 | $197 |
| % Margin | 47.9% | 39.7% | 40.4% | 30.8% |